Congress extends R&D tax credit in bailout
The emergency $700 billion bailout bill includes some good news for biopharma companies. Congress extended the research and development tax credit by two years. The credit had expired at the end of last year.
"In today's challenging economic environment, R&D is a critical catalyst for American innovation, economic growth, and job creation," said the R&D Tax Coalition in a statement. "The R&D tax credit motivates U.S.-based companies to keep cutting-edge research projects in the United States while funding high wage and high skilled jobs for American R&D workers across diverse industries such as manufacturing, information technology, biotech, agriculture, aerospace and others."
- check out the story from IDG News
Related Articles:
Financial crisis clouds the future of biopharma
Economy catches up with biotech investing
Can we improve on the RTC bailout model?
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
